Ginex, TizianaMarco-Marín, ClaraWieczor, MiłoszMata, Carlos P.Krieger, JamesRuiz-Rodriguez, PaulaLópez-Redondo, Maria LuisaFrancésc-Gómez, ClaraMelero, RobertaSánchez-Sorzano, Carlos OscarMartínez, MartaGougeard, NadineForcada-Nadal, AliciaZamora-Caballero, SaraGozalbo-Rovira, RobertoSanz-Frasquet, CarlaArranz, RocíoBravo, JeronimoRubio, VicenteMarina, AlbertoGeller, RonComas, IñakiGil, CarmenCoscolla, MireiaOrozco López, ModestoLlácer, José LuisCarazo, Jose-Maria2023-02-032023-02-032022-07-111553-7366https://hdl.handle.net/2445/193026The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies character-izing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness28 p.application/pdfengcc-by (c) Ginex, Tiziana et al., 2022https://creativecommons.org/licenses/by/4.0/SARS-CoV-2InfeccionsMutació (Biologia)VacunesSARS-CoV-2InfectionsMutation (Biology)Vaccinesinfo:eu-repo/semantics/article7248662023-02-03info:eu-repo/semantics/openAccess